CymitQuimica logo

CAS 1809010-50-1

:

Berotralstat

Description:
Berotralstat is a small molecule drug primarily developed for the treatment of hereditary angioedema (HAE), a genetic condition characterized by recurrent episodes of severe swelling. It functions as a selective inhibitor of the plasma kallikrein enzyme, which plays a crucial role in the bradykinin pathway, leading to the symptoms associated with HAE. The chemical structure of berotralstat includes specific functional groups that contribute to its pharmacological activity and selectivity. It is typically administered orally and has been shown to reduce the frequency of angioedema attacks in patients. The substance is characterized by its moderate solubility in aqueous solutions and a favorable pharmacokinetic profile, allowing for effective systemic absorption. Safety and efficacy profiles have been evaluated in clinical trials, demonstrating its potential as a therapeutic option for individuals suffering from this debilitating condition. As with any medication, monitoring for side effects and interactions with other drugs is essential during treatment.
Formula:C30H26F4N6O
Synonyms:
  • Berotralstat (BCX-7353)
  • Berotralstat
  • 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)[(cyclopropylmethyl)amino]methyl]-2-fluorophenyl]-3-(trifluoromethyl)-
  • Berotralstat (BCX7353, BCX-7353)
  • Berotralstat Crude
  • (R)-1-(3-(Aminomethyl)phenyl)-N-(5-((3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.